top of page

Discussion with the Medical Products Agency regarding the risk RA population

  • Writer: PMO team
    PMO team
  • Feb 10, 2022
  • 1 min read

We have developed a Regulatory briefing book in RTCure. This has informed our regulatory discussions, identifying key issues such as the identification of unmet need, well-defined criteria to identifying patients at risk, and care pathway analysis with information on costs of early intervention vs potential savings to the society would be required. This document was the basis of initial discussion with the Swedish Medical Products Agency. Read it here!


 
 
 

Recent Posts

See All
PRP Newsletter - May 2020

Following this link you can find the EULAR Patient Research Partners newsletter of May 2020. This newsletter contains an invitation to...

 
 
 

Comments


  • twitter

Follow us on Twitter:

The RTCure project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement no 777357. This joint undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

The communication reflects the author's view; neither IMI nor the European Union or EFPIA  are responsible for any use that may be made of the information contained herein.

bottom of page